Candida albicans is both the most common fungal commensal microorganism in healthy
individuals and the major fungal pathogen causing high mortality in at-risk populations …

Following the widespread use of immunosuppressive therapy and broad-spectrum
antimycotic prophylaxis, C. glabrata has emerged as an important opportunistic pathogen in …

Mucocutaneous fungal infections are typically found in patients who have no known immune
defects. We describe a family in which four women who were affected by either recurrent …

Current understanding of resistance and susceptibility to vulvovaginal candidiasis
challenges existing paradigms of host defence against fungal infection. While abiotic biofilm …

Vulvovaginal candidiasis (VVC), caused by Candida albicans, remains a significant problem
in women of childbearing age. While cell‐mediated immunity is considered the predominant …

For over 3 decades, investigators have studied the pathogenesis of vulvovaginal candidiasis
(VVC) and recurrent VVC (RVVC) through clinical studies and animal models. While there …

Host defense responses of the human female genital tract mucosa to pathogenic microbes
and viruses are mediated in part by the release of antimicrobial substances into the …

Vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are frequently encountered in
clinical practice. Recent advances have furthered understanding of pathophysiology. Proper …

We previously reported that a bi-phasic innate immune MAPK response, constituting
activation of the mitogen-activated protein kinase (MAPK) phosphatase MKP1 and c-Fos …

Instead of vulvovaginal candidiasis being caused by defective or dysfunctional CD4+ T
helper 1-type cell-mediated immune reactivity, data suggest that symptomatic vulvovaginal …